Sign in →

Test Code HERDN HER2, Breast, DCIS, Quantitative Immunohistochemistry, Manual No Reflex


Advisory Information


This test is only for ductal carcinoma in situ or solid/intracystic papillary carcinoma breast tissue. For gastroesophageal cancer, order HERGM / HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual or HERGN / HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual, No Reflex.



Shipping Instructions


Attach the green pathology address label included in the kit to the outside of the transport container.



Necessary Information


Include accompanying pathology report stating the final diagnosis.



Specimen Required


Specimen Type:

Preferred: A paraffin-embedded tissue block containing breast cancer tissue that has been fixed in 10% neutral buffered formalin within 1 hour from surgical collection time and for a total of 6 to 72 hours and shipped at ambient temperature

Acceptable: 2 unstained sections, containing breast carcinoma, on charged slides cut at 4 microns less than 1 month ago and shipped at ambient temperature. Tissue on the slides should have been fixed in 10% neutral buffered formalin within 1 hour from surgical collection time and for a total of 6 to 72 hours.

Supplies: Pathology Packaging Kit (T554)

Container/Tube: Pathology Packaging Kit (T554)

Collection Instructions:

1. Submit paraffin-embedded tissue block from ductal carcinoma in situ or solid/intracystic papillary carcinoma breast carcinoma tissue.

2. Paraffin blocks will be returned with final report.


Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

Pathology Test Request Form (T246) (http://www.mayomedicallaboratories.com/it-mmfiles/pathology-request-form.pdf)

Oncology Test Request Form (T729) (http://www.mayomedicallaboratories.com/it-mmfiles/oncology-request-form.pdf)

Useful For

Determining overexpression of HER2 protein on formalin-fixed, paraffin-embedded tissue sections in ductal carcinoma in situ or solid/intracystic papillary carcinoma breast tissue

 

This FDA-approved test is most frequently used to evaluate HER2 overexpression in breast cancer

Method Name

Ventana Pathway Immunoperoxidase Stain with Manual Quantitative Immunohistochemistry

Reporting Name

HER BreastDCIS IHC Manual NO Reflex

Specimen Type

Special

Specimen Minimum Volume

Entire block

Specimen Stability Information

Specimen Type Temperature Time
Special Ambient (preferred)
  Refrigerated 

Reject Due To

Hemolysis

NA

Lipemia

NA

Icterus

NA

Other

NA

Reference Values

Reported as negative (0, 1+), equivocal (2+), and strongly positive (3+) according to the interpretation guidelines for the FDA-approved Ventana Pathway HER2 (4B5) antibody.

Day(s) and Time(s) Performed

Monday through Friday

Analytic Time

2 days

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

88360

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HERDN HER BreastDCIS IHC Manual NO Reflex In Process

 

Result ID Test Result Name Result LOINC Value
71499 Interpretation In Process
71500 Participated in the Interpretation No LOINC Needed
71501 Report electronically signed by In Process
71502 Material Received 81178-6
MA027 Tumor classification In Process
71624 Disclaimer 62364-5
71838 Case Number In Process